Under construction – not a live service

Skip to content

Frontlight Research

Institution

Ottawa Hospital

Ottawa, CanadahealthcareWebsite

Also known as: L'Hôpital d'Ottawa

131running trials
36closed trials
0trials confirmed by the site in the last 60 days
–languages not stated

The site has not confirmed any trial yet.

Running trials

Not yet recruiting
SPIRO-First: A Pragmatic Primary Care-Embedded Pilot Trial of Renin-Guided First-Line Antihypertensive Therapy
NCT07687160· Phase 4· Source
Not yet recruiting
Mycophenolate After Stem Cell Transplant for Systemic Sclerosis
NCT07734012· Phase 2· Source
Not yet recruiting
Cardiac CT Angiography in Acute Stroke Imaging (SCOPE-CT)
NCT07896889· Source
Not yet recruiting
Phase II Study of CAmizestrant in Resectable Endometrial Adenocarcinoma
NCT07840443· Phase 2· Source
Recruiting
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654· Phase 3· Source
Recruiting
Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder
NCT06943573· Phase 2· Source
Recruiting
The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity
NCT06494878· Phase 3· Source
Recruiting
Safety of Perioperative Anticoagulation Management in People With Active Cancer Undergoing Cancer-Related Surgery or Procedures (ACE-HIGH Study)
NCT07372716· Source
Recruiting
Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
NCT07304154· Phase 1· Source
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497· Phase 3· Source
Recruiting
Canadian Consortium on Airway Mucus Occlusions in Asthma, COPD and Chronic Cough
NCT06858748· Source
Recruiting
First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)
NCT07216066· Phase 1· Source
Recruiting
Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)
NCT06983821· Phase 3· Source
Recruiting
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
NCT07175285· Source
Recruiting
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437· Phase 2/3· Source
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868· Phase 2/3· Source
Not yet recruiting
Do Blood Tests Help to Decide Which Patients With Flares of Chronic Obstructive Pulmonary Disease (COPD) Need Antibiotics and Steroids?
NCT06929767· Phase 4· Source
Recruiting
A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes
NCT07112339· Phase 4· Source
Recruiting
DIALysis With EXpanded Solute Removal
NCT06660277· Source
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07005102· Phase 2/3· Source
Recruiting
Personalized Hypoglycemia Outpatient Treatment - a Feasibility Study
NCT07094529· Source
Recruiting
Feasibility Trial for a Right Ventricular Failure Platform Trial
NCT06570473· Phase 2· Source
Enrolling by invitation
A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
NCT07038447· Phase 1· Source
Recruiting
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
NCT06937086· Phase 3· Source
Recruiting
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
NCT06937099· Phase 3· Source
Recruiting
Left Atrial Imaging Prior to Cardioversion: Leveraging Computed Tomography to Rule Out Thrombus in The Emergency Department (LA CLOTTED)
NCT07002450· Source
Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872· Phase 3· Source
Active, not recruiting
A Study to Evaluate Efficacy, Safety and Tolerability of Hydroxychloroquine in Subjects With Parkinson's Disease
NCT06816810· Phase 2· Source
Recruiting
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
NCT06782490· Phase 2· Source
Recruiting
Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis
NCT06256575· Source
Recruiting
The Dragon PLC Trial (DRAGON-PLC)
NCT06914648· Source
Recruiting
Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure
NCT06957366· Source
Recruiting
Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
NCT06421675· Phase 2· Source
Recruiting
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT06618287· Phase 1/2· Source
Recruiting
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
NCT06208735· Phase 1· Source
Active, not recruiting
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247· Phase 3· Source
Active, not recruiting
SpaceIT Hydrogel System for Perirectal Spacing
NCT06451614· Source
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786· Phase 3· Source
Active, not recruiting
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
NCT06447168· Source
Recruiting
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
NCT06561048· Phase 3· Source
Active, not recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515· Phase 1· Source
Active, not recruiting
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824· Phase 3· Source
Active, not recruiting
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT06413498· Phase 3· Source
Active, not recruiting
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
NCT06384261· Phase 2· Source
Active, not recruiting
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
NCT06483334· Phase 1/2· Source
Recruiting
Early Diagnosis and Treatment of Undiagnosed Asthma or COPD: THE UCAP 2 TRIAL
NCT06392776· Source
Recruiting
Pancreatic Insulin Production Capacity (PIPC) - a Feasibility Study
NCT06462170· Source
Recruiting
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT06393374· Phase 3· Source
Active, not recruiting
A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis
NCT06294925· Source
Active, not recruiting
VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study
NCT06249555· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Researchers

No researcher is linked here yet.

Closed trials

Terminated
Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer
NCT05849129· Phase 2· Source
Withdrawn
The UCAP 2 Pilot Study
NCT06014840· Source
Completed
RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine
NCT05513560· Phase 2/3· Source
Completed
Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15
NCT05546476· Phase 2· Source
Completed
Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
NCT05218499· Phase 2/3· Source
Completed
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
NCT05064059· Phase 3· Source
Terminated
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
NCT05090566· Phase 2· Source
Completed
Study of WVE-003 in Patients With Huntington's Disease
NCT05032196· Phase 1/2· Source
Completed
RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department
NCT04485195· Phase 4· Source
Completed
An Observational Study to Evaluate the Clinical Utility of the Oncomine Precision Assay Within the Exactis Network
NCT04564079· Source
Completed
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients
NCT04243122· Phase 2· Source
Terminated
HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)
NCT04684914· Phase 2· Source
Completed
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
NCT03776071· Phase 3· Source
Completed
A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy
NCT04266795· Phase 2· Source
Completed
A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes
NCT04560998· Phase 3· Source
Completed
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
NCT04210115· Phase 3· Source
Completed
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
NCT04209855· Phase 3· Source
Completed
Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT03781063· Phase 2· Source
Completed
I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).
NCT03939689· Phase 2· Source
Completed
Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer
NCT03941093· Phase 3· Source
Completed
A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)
NCT03516981· Phase 2· Source
Completed
PSMA-PET Registry for Recurrent Prostate Cancer
NCT03718260· Source
Completed
This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)
NCT03599245· Phase 3· Source
Terminated
WAVe Study - Weight Adjusted Dalteparin for Patients Over 90 kg With Acute Cancer Associated Venous Thromboembolism
NCT03297359· Phase 2· Source
Completed
Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma
NCT03391466· Phase 3· Source
Completed
Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?
NCT03269994· Phase 3· Source
Completed
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
NCT03274492· Phase 3· Source
Completed
A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma
NCT03332017· Phase 2· Source
Completed
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain
NCT03213457· Phase 3· Source
Completed
Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis
NCT03232073· Phase 3· Source
Completed
Folic Acid Clinical Trial: Follow up of Children (FACT 4 Child)
NCT03269110· Source
Completed
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)
NCT03112174· Phase 3· Source
Completed
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
NCT02975934· Phase 3· Source
Completed
Undiagnosed COPD and Asthma Population Study (UCAP)
NCT03148210· Source
Completed
Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
NCT03040999· Phase 3· Source
Completed
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)
NCT03036488· Phase 3· Source

Trial sites

Conditions

Diseases this institution publishes on or runs trials for.

Bipolar disorder21 works · 1 trials

Institution data: ROR 03c62dg59 (CC0-1.0)Updated 10 Nov 2026

Report an error

Under construction, not live – Ottawa Hospital: trials and research groups – Frontlight Research